TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22947843
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group, n=10)
Study: 18787352
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (DOC)
Study: 18787352
Drug: Weekly vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vinorelbine (VIN)
Study: 18787352
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment (X-DOC)
Study: 18787352
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment (X-VIN)
Study: 16004670
Drug: CC plus
Normalized name: STATLOCK PICC PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC plus HS (Clomiphene Citrate plus Hormone Supplementation)
Study: 7795283
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily, every other day)
Study: 2201794
Drug: Topical low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical low dose heparin (0.125 gm./l., 25,000 units per l.)
Study: 2201794
Drug: Glycine solution
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine solution alone (control)
Study: 31130666
Drug: KP extract
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP extract 90 mg/day
Study: 31130666
Drug: KP extract
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP extract 180 mg/day
Study: 24627207
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intraventricular tissue plasminogen activator (TPA) every 12 h (maximum 10 mg)
Study: 16630999
Drug: lixivaptan 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: lixivaptan 10, 30, 75, 150, 250, or 400 mg
Study: 16630999
Drug: lixivaptan (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: lixivaptan (higher doses)
Study: 10577530
Drug: Photocoagulation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photocoagulation and aspirin treatment
Study: 8561333
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anesthesia (CSA) with 5 mg of 0.5% hyperbaric bupivacaine, followed by optional reinjection of 2.5 mg every 5 min
Study: 8561333
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anesthesia (SDSA) with 10-15 mg of 0.5% hyperbaric bupivacaine
Study: 8561333
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anesthesia (SDSA)
Study: 2008876
Drug: 4-6 140-mL
Normalized name: gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-6 140-mL cups filtered decaffeinated coffee per day and 75 mg caffeine pills
Study: 2008876
Drug: 4-6 140-mL
Normalized name: gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-6 140-mL cups filtered decaffeinated coffee per day and placebo pills
Study: 6351333
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (10 mg) after intramuscular atropine (0.6 mg)
Study: 6351333
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (control) after intramuscular atropine (0.6 mg)
Study: 29401529
Drug: Tissue flossing
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue flossing (3 treatments lasting 2 minutes each)
Study: 29231589
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of soft capsule of Vitamin E, once a day for 28 days
Study: 14617718
Drug: acetylcholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetylcholinesterase inhibitor (donepezil)
Study: 9039344
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (up to 0.25 U/kg/week in daily doses)
Study: 8249050
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patches (three different doses applied to different groups)
Study: 1916494
Drug: Metronidazole 20
Normalized name: metronidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 20 mg/kg
Study: 1916494
Drug: Metronidazole 10
Normalized name: metronidazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 10 mg/kg
Study: 1916494
Drug: Metronidazole (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (combined 20 mg/kg and 10 mg/kg)
Study: 393035
Drug: Oral retinoid
Normalized name: tretinoin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral retinoid (25 mg three times a day for six weeks)
Study: 30514775
Drug: DC–CIK infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC–CIK infusions
Study: 22855271
Drug: Vardenafil (0.3-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (0.3-3 mg/kg) in rats; administered orally 30 min before testing.
Study: 22855271
Drug: Vardenafil (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (10-20 mg) in humans; administered 85 min before testing.
Study: 22855271
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in humans; administered 85 min before testing.
Study: 8210543
Drug: Thymopentin 50
Normalized name: Thymopentine
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin 50 mg s.c. every other day, after irradiation for at least 6 cycles of 4 weeks each
Study: 28293470
Drug: ABT‐436 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐436 800 mg QD
Study: 26430826
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (2 capsules/day for 8 weeks)
Study: 26430826
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules/day for 8 weeks)
Study: 21830124
Drug: Chemotherapeutics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutics plus verapamil infusion
Study: 21830124
Drug: Targeted intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Targeted intra-arterial infusion (control)
Study: 19219314
Drug: Radial shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shockwave treatment (three applications, once a week)
Study: 17309575
Drug: Midodrine hydrochloride
Normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine hydrochloride (MID) at 4 mg/day
Study: 17309575
Drug: L-threo-3,4-dihydroxyphenylserine (L-DOPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threo-3,4-dihydroxyphenylserine (L-DOPS) at 400 mg/day
Study: 12378829
Drug: Strontium salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium salt (oral administration at low dosage)
Study: 12378829
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intermittent fluoride therapy
Study: 12378829
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I and other growth factors
Study: 7665724
Drug: Mitoxantrone (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (cumulative dose of 96 mg/m2)
Study: 2501110
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) Buserelin (300 micrograms three times a day)
Study: 2501110
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) Buserelin implant (6.6 mg Buserelin)
Study: 782796
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol (400 mug daily)
Study: 26039125
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity lifestyle modification (LILM) program for 6 months, including 4 interactive group discussion sessions and weekly phone contact with volunteer counselors.
Study: 23344468
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose prednisolone (1 mg/Kg/dose 24 h before surgery)
Study: 23344468
Drug: 5-day prednisolone
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day prednisolone (1 mg/Kg/day before operation)
Study: 20715901
Drug: Sourdough prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sourdough prepared with L. plantarum
Study: 17081831
Drug: Universal-free school
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal-free school breakfast offered in treatment schools for three consecutive school years (2000-2001 to 2002-2003)
Study: 15466731
Drug: Electrohydraulic high-energy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrohydraulic high-energy shock waves treatment
Study: 7970842
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg p.o. daily for 7 days pre-operatively)
Study: 3315282
Drug: (2"R)-4'-O-tetrahydropyranyladriamycin (THP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) 10-55 mg/m2 administered by i.v. bolus injection daily for acute leukemia
Study: 3315282
Drug: (2"R)-4'-O-tetrahydropyranyladriamycin (THP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) administered according to three different schedules for malignant lymphoma: daily, weekly or once every 3-4 weeks
Study: 29228206
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment group (n = 33)
Study: 29228206
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment group (n = 34)
Study: 27927951
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg S44819
Study: 27927951
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg S44819
Study: 21109115
Drug: β-blocker treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker treatment initiated >1 to 4 weeks before surgery
Study: 21109115
Drug: β-blocker treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker treatment initiated >4 weeks before surgery
Study: 21109115
Drug: β-blocker treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker treatment initiated <1 week before surgery
Study: 17511802
Drug: Chemotherapy every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy every 4 weeks (cisplatin-paclitaxel or carboplatin-paclitaxel)
Study: 17511802
Drug: Chemotherapy every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy every 3 weeks (cisplatin-paclitaxel or carboplatin-paclitaxel)
Study: 17511802
Drug: Early-stage disease
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-stage disease (chemotherapy every 4 weeks)
Study: 12714865
Drug: lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 20 mg o.d.
Study: 12714865
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg o.d.
Study: 12714865
Drug: lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 20 mg o.d. (responders only)
Study: 12714865
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg o.d. (responders only)
Study: 8652784
Drug: Intelligent control
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intelligent control system for insulin dosage recommendations
Study: 6238315
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg administered intravenously
Study: 6238315
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg associated with noramidopyrine
Study: 28171855
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (n = 98)
Study: 28171855
Drug: Standard-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose group (n = 65)
Study: 26048730
Drug: TXA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 500 mg intra-articular injection
Study: 26048730
Drug: Saline intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intra-articular injection (control)
Study: 23740284
Drug: Dobutamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (5 mcg/kg/min fixed-dose)
Study: 12093655
Drug: Topical IOP-lowering
Normalized name: Avena sativa flowering top
DrugBank: Avena sativa flowering top (DB14253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical IOP-lowering treatment (mainly beta-blockers)
Study: 12093655
Drug: Topical IOP-lowering
Normalized name: Avena sativa flowering top
DrugBank: Avena sativa flowering top (DB14253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical IOP-lowering treatment (n = 33)
Study: 10362413
Drug: 546C88 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 546C88 at 1 mg/kg/hr
Study: 10362413
Drug: 546C88 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 546C88 at 2.5 mg/kg/hr
Study: 10362413
Drug: 546C88 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 546C88 at 5 mg/kg/hr
Study: 10362413
Drug: 546C88 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 546C88 at 10 mg/kg/hr
Study: 10362413
Drug: 546C88 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 546C88 at 20 mg/kg/hr
Study: 8750372
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg alone
Study: 8750372
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg with losartan 50 mg
Study: 2053226
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of norfenefrine
Study: 6365516
Drug: Milk-based formula
Normalized name: Formula, Infant Oral Powder for Suspension [TUGABOOS MILK-BASED FORMULA W/IRON]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based formula supplement providing 800 kcal and 40 g protein daily
Study: 6365516
Drug: Milk-based formula
Normalized name: Formula, Infant Oral Powder for Suspension [TUGABOOS MILK-BASED FORMULA W/IRON]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based formula supplement
Study: 30711327
Drug: Inhalation aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aromatherapy with lavender essence
Study: 27767433
Drug: Acupuncture (n=15);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (n=15); treatment for 30 days, once weekly for 5 sessions.
Study: 27767433
Drug: Carprofen (4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (4.4 mg/kg, PO, q 24 h; n=16); treatment for 30 days.
Study: 27767433
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose capsules, 1 mg/kg, PO, q 24 h; n=16); treatment for 30 days.
Study: 24072404
Drug: Implant removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant removal patients (N=38)
Study: 20930165
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (multicomponent treatment including aspirin)
Study: 14689885
Drug: Catheter depth
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter depth of 2 cm and infused semen volume of 0.3 ml
Study: 14689885
Drug: Catheter depth
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter depth of 1 cm and infused semen volume of 0.5 ml
Study: 14689885
Drug: Catheter depth
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter depth of 1 cm and infused semen volume of 0.3 ml
Study: 14689885
Drug: Catheter depth
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter depth of 2 cm and infused semen volume of 0.5 ml
Study: 14689885
Drug: Catheter depth
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter depth of 3 cm and infused semen volume of 0.5 ml
Study: 14689885
Drug: Catheter depth
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter depth of 3 cm and infused semen volume of 0.3 ml
Study: 10494584
Drug: Intravenous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nicotine (0, 3.5, 7, 14, and 28 micrograms/kg)
Study: 1816570
Drug: Triazolam (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125, 0.25 and 0.5 mg/70 kg of body weight)
Study: 6752963
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diazepam suppositories
Study: 22704391
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL saline solution im)
Study: 17379432
Drug: Cevimeline 30
Normalized name: Cevimeline 30mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevimeline 30 mg three times daily (with possible escalation to 45 mg)
Study: 17379432
Drug: Cevimeline 30-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevimeline 30-45 mg three times daily
Study: 25992746
Drug: Fixed course
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed course of antibiotics for 4±1 calendar days
Study: 25992746
Drug: Antibiotics until
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics until 2 days after resolution of fever, leukocytosis, and ileus, maximum of 10 days
Study: 19696287
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material of 300 mg I/mL (Protocol A)
Study: 19696287
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material of 370 mg I/mL (Protocol B)
Study: 19696287
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material of 370 mg I/mL plus saline flush (Protocol C)
Study: 16809571
Drug: 25% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% human albumin (ALB) infusion, doses ranging from 0.34 to 2.05 g/kg, administered over 2 hours within 16 hours of stroke onset
Study: 16809571
Drug: Standard-of-care intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care intravenous tissue plasminogen activator (tPA)
Study: 12777860
Drug: Anti-CD25 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD25 monoclonal antibody (daclizumab)
Study: 1540491
Drug: (+)-R-nitrendipine 20
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-R-nitrendipine 20 mg
Study: 1540491
Drug: (-)-S-nitrendipine 20
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-S-nitrendipine 20 mg
Study: 1540491
Drug: R,S-nitrendipine (pseudoracemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: R,S-nitrendipine (pseudoracemic mixture of 10 mg (+)-R and 10 mg (-)-S)
Study: 31982540
Drug: Regular paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular paracetamol
Study: 31982540
Drug: Paracetamol as-needed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol as-needed
Study: 26543177
Drug: v‐gel supraglottic
Approvals — FDA: no, EMA: no, PMDA: no
Description: v‐gel supraglottic airway device (SGAD)
Study: 19147639
Drug: Topical chloramphenicol
Normalized name: chloramphenicol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chloramphenicol (n=488)
Study: 19147639
Drug: Paraffin ointment
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin ointment (n=484; placebo)
Study: 16785075
Drug: Citracal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citracal tablet providing 315 mg of elemental calcium
Study: 16785075
Drug: OsCal tablet
Normalized name: OsCal 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: OsCal tablet providing 500 mg of elemental calcium
Study: 16785075
Drug: People's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: People's Choice tablet providing 600 mg of elemental calcium
Study: 16785075
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate tablet
Study: 11034038
Drug: Oral phytonadione
Normalized name: Phytonadione
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phytonadione 2.5 mg
Study: 9063425
Drug: Antihistamine-decongestant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine-decongestant combination (ADC) - brompheniramine maleate-phenylpropanolamine hydrochloride
Study: 9063425
Drug: Antihistamine-decongestant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine-decongestant combination (ADC)
Study: 7981078
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (Peptichemio, vincristine, and prednisone)
Study: 7981078
Drug: MPH-P and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH-P and combination chemotherapy
Study: 4527847
Drug: CAPA (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPA (cyclophosphamide, cytosine arabinoside, prednisolone, and L asparaginase)
Study: 26135582
Drug: Pharmacist in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist in a community pharmacy with predefined training in performing medication reviews
Study: 18192779
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy in primary HIV infection